prmarks logo

Biocon Biologics Announces New Dermatology Data to Be Presented at EADV Congress 2024

News provide by
702Padmin
Sep 24, 2024, 22:05 PM PDT

Share this article

Switching between adalimumab and adalimumab-fkjp in Phase 3 study in patients with chronic plaque psoriasis supports interchangeability between adalimumab and adalimumab-fkjp Biosimilarity between Bmab 1200 and reference biologic-Ustekinumab in pivotal Phase 3 trial in patients with…